Samsung SDI and KG Mobility Forge Alliance to Co-Develop Next-Gen 46-Series EV Batteries
Samsung SDI and KG Mobility have signed an MOU to jointly develop advanced EV battery packs using next-generation 46-series cylindrical cells, signaling a deeper integration trend in the auto industry.
South Korean battery giant and automaker have signed a memorandum of understanding (MOU) to jointly develop advanced technologies for future electric vehicles (EVs). According to a company announcement on Tuesday, the partnership will focus on utilizing 's to power 's upcoming EV lineup.
At the core of the deal is the battery, a next-generation form factor gaining traction in the industry. stated that its version offers high energy density, which translates to longer driving ranges and faster charging capabilities.
The company also emphasized the battery's enhanced safety and durability, ensuring "reliable performance under diverse driving conditions." By co-developing the itself, aims to tightly integrate this technology, optimizing it for the specific design and performance goals of its future vehicles.
This agreement extends beyond a simple supplier-client relationship. confirmed that the two companies will also exchange information on global battery markets and pursue broader strategic cooperation, including joint research and development projects. It's a move that signals a deeper integration between automakers and their battery suppliers as the industry's electric transition accelerates.
本コンテンツはAIが原文記事を基に要約・分析したものです。正確性に努めていますが、誤りがある可能性があります。原文の確認をお勧めします。
関連記事
米FDAが、ノボノルディスク社の人気肥満症治療薬「ウゴービ」の経口薬(ピル)を承認。注射と同等の効果を持ち、利便性が大幅に向上。2026年初頭に米国で発売予定。
米連邦通信委員会(FCC)が、国家安全保障上のリスクを理由に、外国製の新型ドローンの米国への輸入を原則禁止。DJIなど大手メーカーへの影響と、技術サプライチェーンの今後を分析します。
ライティング、デザイン、コーディング、チャットボット機能を統合したAIプラットフォーム「AI MagicX」が、通常価格972ドルの生涯プランを59.97ドルで提供。複数の有料ツールを一つにまとめ、コストと時間を節約します。
米国FDAがノボノルディスク社の人気肥満治療薬「ウェゴビー」の経口錠剤版を承認。週1回の注射に代わる1日1回の服用オプションとして、臨床試験での有効性や競合製品との比較を解説します。